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Abstract 
Background and Aim: Left ventricular dysfunction is a frequent complication after coronary artery bypass graft 
(CABG) and is often treated with inotropic drugs to achieve suitable hemodynamic status. Bone marrow-derived 
mesenchymal stem cells (BMSCs) have potential effects on cardiac function. In this study, we aimed to identify the 
predictor role of MSCs in taking inotropic drugs in patients with severe left ventricular dysfunction undergoing CABG.  
Methods: The study included 30 patients who underwent off-pump CABG at Afshar Hospital and Seyed Al-Shohada 
Hospital. For investigating the possible association of BMSCs proliferation rate with taking inotropic drugs, the bone 
marrow samples aspired from patients' sternum during surgery. MSCs were isolated and counted after 4, 7, and 14 days 
using trypan-blue color, and then doubling times were calculated.  
Results: After cardiac surgery, the number of female patients who take inotropic drugs was significantly higher than 
men. Our data showed that the BMSCs doubling time in female patients who received inotropic drugs was less than 
that of male patients who received inotropic drugs (p < 0.05).  
Conclusion: Based on this investigation, we concluded that there was a clear relevance between the MSCs' doubling 
time and the inotropic drug requirements in patients who received inotropic drugs. 
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Introduction 
Permanent increasing myocardial infarction is one 
of the leading causes of death worldwide (1). 
Coronary artery bypass graft (CABG) is the most 
effective remedy for the cure of patients with 
myocardial infarction (2). One of the complication 
status in patients after myocardial infarction is the 
reductions in cardiac contractility, and therefore, 
improving the hemodynamic status and improving 
the cardiac function of patients during and after 
surgery is very important (2-4). Reduction in the 
myocardial muscle contraction can lead to systemic 
hemodynamic effects, including the loss of blood 
flow to vital organs (4). After cardiac surgery, 
patients often received inotropic drugs to maintain 
adequate hemodynamic status, including cardiac 
muscle contractility. These agents are a drug group 
that has an impact on myocardial contractility and 
improve cardiac function (5-7). Positive inotropic 
agents, including levosimendan and dopamine, 
strengthen the muscular contraction.In contrast, 
harmful inotropic agents, including calcium 
antagonists and ß‐blockers, decrease the force of 
muscular contractions (8, 9). The detection of a 
predictor factor for taking inotropic drugs in 
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patients would be a valuable strategy for improving 
cardiac performance. Previous studies have 
described the functional benefits of bone marrow-
derived mesenchymal stem cells (BMSCs) in 
patients with severe left ventricular dysfunction 
(10-12). BMSCs are adult multipotent stem cells 
that have a potential pattern in tissue repairment 
(13). These cells have been used in the regeneration 
of injured cardiac tissue and were able to 
differentiate into cardiomyocytes (14, 15).  
Besides, many studies confirm the beneficial or 
protective effects of BMSCs in cardiac function 
after surgery (16, 17). Therefore, the current study 
was planned to detect BMSCs doubling time in 
patients with severe left ventricular dysfunction 
undergoing coronary artery bypass graft (CABG) 
who required and received inotropic drugs.  
Methods 
Patients and Study Design 
The present study included 30 patients with severe 
left ventricular dysfunction. After approval by the 
Ethics Committee of Shahid Sadoughi University of 
Medical Sciences with this code 
(IR.SSU.MEDICINE.REC.1397.199), bone marrow 
samples from all patients with ejection 
fraction ≤ 30% who underwent CABG surgery at 
Seyed Al-Shohada hospital and Afshar hospital 
were collected. A written informed consent before 
study entry was filled by patients.  
Culture and characterization of human BMSc 
1 mL bone marrow samples had aspired from 
sternum during surgery from patients, and bone 
marrow MSCs were isolated at the cell culture 
laboratory. Briefly, isolated BMSCs were grown in 
minimum essential medium (αMEM) culture 
medium supplemented with 20% fetal bovine serum 
(FBS) containing 5% CO2 at 370C. For 
characterizing the BMSCs, the presence of 
hematopoietic markers CD34 and CD45 and 
mesenchymal markers CD90 and CD105 were 
examined by a flow cytometer (FACS Calibur 
Becton, Dickinson, USA). Briefly, BMSCs were 
detached (with trypsin/EDTA) from 25 cm2 flasks 
after 14 days and counted.  
About 106 Cell suspension was distributed into 
aliquots and centrifuged at 1500 rpm for 5 min, and 
then, the pellets were resuspended in PBS. Samples 
were incubated with appropriate antibodies, 
including anti CD90, CD105, CD34, and CD45 for 
1 hour and read by a flow cytometer. 
BMSCs doubling time 
For evaluating the relationship between taking 
inotropic drugs and BMSCs proliferation rate, 
doubling times for all patients were assessed. 
Briefly, 104 cells were plated in 6-well plates, and 
then cells were trypsinized and counted in 4, 7, and 
14 days applying trypan blue color and a 
hemocytometer.  
The acquired results from the counted BMSCs were 
plotted, and doubling times were calculated from 
the log phase of the growth curve. 
Statistical analysis 
All results were figured out by the Graphpad Prism 
Version 8 software (GraphPad Software, San 
Diego, CA, USA). All consequences are presented 
as mean±standard deviation (SD). The mean 
differences between groups were compared using 
the two-way ANOVA. Statistical significance 
difference was indicated as p <0.05.  
Results 
In this study, 30 patients (18 men and 12 women) 
with severe left ventricular dysfunction were 
included. For appraising the possible relevancy 
between MSCs proliferation rate and taking 
inotropic drugs, a 1 mL bone marrow sample from 
the sternum of patients was aspired for BMSCs 
isolation and doubling time calculation during 
surgery. Human BMSCs are shown in Figure 1. For 
confirmation of human BMSC, a flow cytometry 
method was used. The flow cytometry diagrams are 
displayed in Figure 2.  
The cells were positive for mesenchymal markers 
CD105 and CD90 and negative for hematopoietic 
markers CD34 and CD45. The expression rate of 
CD105 and CD90 markers was 99.2% and 98.7%, 
respectively (Figure 2A and Figure 2B). Also, the 
expression of CD34 and CD45 markers was 0.249% 
and 0.945%, respectively (Figures 2C and 2D). 
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Figure 1. BMSCs after isolation and culture. 
The association between postoperative 
inotropic drugs requirements and BMSCs 
doubling-time 
Figure 3A indicates that in 18 male studied 
patients, three of them received inotropic drugs 
after surgery, while nine female patients received 
inotropic drugs after surgery. Therefore, the 
percentage of women female patients who require 
inotropic medication was higher than that of male 
patients with similar circumstances (p=0.0024). 
The odds ratio in this study was 15, meaning that 
taking inotropic drugs in female patients is 15 
times more often than men (Figure 3A). Figure 3B 
represents that the mean of BMSCs doubling time 
in female patients (205 ± 65) who received 
inotropic drugs was less than that of male patients 
(327 ± 59) who received inotropic drugs (p < 
0.05). There was no difference in BMSCs 
doubling time in males (211 ± 54) and females 
(196 ± 16) patients who did not use medication.  
  
  
Figure 2. A) Flow cytometry diagram of CD90 mesenchymal antibody. B) Flow cytometry diagram of CD105 
mesenchymal antibody. C) Flow cytometry diagram of CD34 hematopoietic antibody. D) Flow cytometry 




Association between Bone Marrow Mesenchymal Stem Cell …                                                    Esmailidehaj M, et al. 
Archives of Medical Laboratory Sciences; Volume 6, 2020 (Continuous Volume)  4 
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License 
  
Figure 3. A) The inotropic drug requirements in male and female patients. B) The association between MSCs 
doubling time and taking inotropic drugs in males and females. The data is shown as a mean ± standard deviation. 
Statistical significance difference was indicated as p <0.05. 
 
Discussion 
The main results of this study can be summarized as 
follows: after surgery, the mean of BMSCs 
doubling time in female patients who received 
inotropic drugs was less than that of male patients. 
There was no difference in the BMSCs doubling 
time in male and female patients who did not 
receive inotropic drugs. 
Left ventricular dysfunction with low ejection 
fraction is joint in patients undergoing CABG 
surgery (18, 19). Despite advancements in surgical 
techniques, the management of patients with severe 
left ventricular dysfunction undergoing CABG 
remains challenging, and patients with ejection 
fraction <30% are at a higher risk for complications 
after surgery. Therefore, early diagnosis of 
perioperative variables to identify higher-risk 
patients  play an active role in the management 
process of patients. In patients undergoing CABG 
surgery, low ejection fraction is associated with 
requirements for inotropic support (18, 20). It is not 
surprising that the prediction of the inotropes' 
requirements might be a strong mortality predictor. 
In many studies, BMSCs have been used to 
improve heart function as a new option for cardiac 
disease therapy (21, 22).  
BMSCs are adult multipotent stem cells that can 
differentiate into a variety of cells, including 
cardiomyocytes (23, 24). There are specific markers 
BMSCs surface. According to studies conducted by 
other researchers and us, the results of flow 
cytometry indicated that the expression of CD105 
and CD90 mesenchymal markers are specific 
features of these cells (25).  
Numerous studies have reported that BMSCs can be 
useful in improving infarcted myocardium. 
Transplantation of stem cells into the infarcted 
region leads to the regeneration of cardiomyocytes 
and the improvement of contractile function of the 
damaged myocardium (26, 27). Therefore, it is 
expected that the proliferation rate of MSCs will 
have a significant relationship with inotropic taking 
requirements and in patients who need inotropic 
administration, doubling time would be shorter. Our 
study proved that the average doubling time in 
female patients with inotropic use is less than male 
patients with inotropic use. But doubling time in 
female and male patients without inotropic use was 
not significantly changed.  
Conclusion 
We concluded that in patients who require inotropic 
administration, doubling time would be shorter. The 
results of the present study showed that the rate of 
MSCs proliferation in female patients who received 
inotropic drugs were  significantly less than that of 
male patients in the same situations.  
The conclusion of this investigation may help 
cardiothoracic surgeons to prospectively identify 
A B 
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those patients who will likely require inotropic 
support after surgery.  
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